Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Covi-MSC with 10 for 10 is looking good for an EUA! And we'll soon hear if Abivertinib can get a cytokine storm prevention EUA. That would leave 6 more potential Covid EUA's. I wonder which would be next?
1. Covi-Stix rapid accurate virus test
2. Covi-Track rapid accurate antibody test
3. Covi-push 2020 injection
4. Covi-Drops 2020 nose drops
5. Covi-Vax 2020 lipid DNA injection($34 million DARPA funding)
6. Abivirtinib cytokine storm prevention
7. Covi-MSC Stem Cell ARDS treatment
8. Covi-Shield antibody cocktail(to deal with variants)
Each of these EUA's could be accompanied by government grants and multi-billion dollar international sales.
Paul is a really smart guy who follows Sorrento closely.
"The TARGET enrollment of 10 patients with acute respiratory failure due to Covid-19 has been ACCOMPLISHED. Please understand what today’s PR is saying, and know the it’s highly likely MSC is already in P2 Trials in both Brazil and the US at multiple sites. Further more as per the March 25 PR, Sorrento was working with the FDA to determine the sample size and data necessary to support a EUA. That determination has been accomplished, and with multiple sites I expect enrollment to already be closed. Expect EUA/government contracts from US, Europe, Brazil, etc... pending data which looks to be May or early June latest. When a person is discharged from ICU, and leaves the hospital healthy within 8 days or less it doesn’t take a crystal ball to figure out the EUA determination."
The target enrollment of 10 patients with acute respiratory failure due to COVID-19 has been accomplished.
All 10 patients were discharged from hospital within three days after their last COVI-MSC infusion.No infusion-related adverse events were observed.Sorrento plans a pivotal, multi-country, multi-site, placebo-controlled study to support an EUA submission.
SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today the completion of enrollment in its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) infusions to treat COVID-19 induced acute respiratory failure (ARD) or acute respiratory distress syndrome (ARDS). This current study (MSC-COV-101) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for up to three infusions for a total of 1 x 106 cells/kg, with patients being followed for 28 days following the final infusion.
A total of 10 patients (8 males/2 females; age range 24-65 years; 8 Caucasian/2 Asian; 7 Hispanic/Latino/3 non-Hispanic/Latino; height 64 to 70 inches; weight 66 to 130 kg) were enrolled and all were discharged from the hospital to home within three days of their last infusion. At baseline, all patients required oxygen supplementation and had PaO2/FiO2 ratios ranging from 135 to 256 (normal ? 400). All patients had various medical co-morbidities in addition to obesity. The 10th patient had been under treatment for nearly 2 weeks without improvement and was discharged after the 2nd COVI-MSC infusion with oxygen saturations in the high 90s on room air. On follow up days later, the patient was still doing well.
Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC™ Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate
4/20/21, 9:00 AM
• The target enrollment of 10 patients with acute respiratory failure due to COVID-19 has been accomplished.
• All 10 patients were discharged from hospital within three days after their last COVI-MSC infusion.
• No infusion-related adverse events were observed.
• Sorrento plans a pivotal, multi-country, multi-site, placebo-controlled study to support an EUA submission."
They plan a PIVOTAL TRIAL likely in US, Brazil and Mexico!
Although pipeline 2 offers more information than the regular pipeline I don't think that it is totally up-to-date! I'm sure we all still have lots of questions.
Pipeline 2 - Sorrento Therapeutics...click on individual items for more information than the regular pipeline !
https://sorrentotherapeutics.com/pipeline-2
ANP Technologies®, Inc. Receives $19.7M from NIH/NIBIB/Rapid Acceleration of Diagnostics (RADx) Program for its NIDS® COVID-19 Antigen Rapid Test Kit
Newark, DE (Apr. 16, 2021) – ANP Technologies Inc. (ANP), announced that it has received a highly competitive Phase 2 award totaling $19.7M from NIH/NIBIB/Rapid Acceleration of Diagnostics (RADx) Tech Program for its NIDS® COVID-19 Antigen Rapid Test Kit. This award is based upon ANP’s successful completion of Phase 0 and Phase 1 efforts in less than three months. The rapid antigen test developed by ANP is a nano-intelligent technology enhanced lateral flow immunoassay test that detects SARS-CoV-2 antigens in nasal samples. The test delivers results in 15 minutes at the point of care and is being validated for potential at-home use. Read more at https://www.nibib.nih.gov/covid-19/radx-tech-program/radx-tech-phase2-awards.
“The NIH/RADx award is a further validation of our NIDS® rapid test technology, which has been fully fielded by the Department of Defense for the detection of various biological agents.” Said Dr. Ray Yin, President and CTO of ANP. “Our plug-and-play assay platform allows us to rapidly develop various rapid tests, including multiplexed lateral flow tests, for the detection of SARS-Cov-2 virus, its variants and emerging biothreats.”
?About ANP Technologies, Inc.?
?ANP Technologies, Inc. is a clinical stage biopharmaceutical company and a world leader in developing innovative nano-therapeutics and nano-diagnostic tests. ANP has been a premier provider to supply its rapid multiplexed lateral flow tests for the detection of various biological agents to the Department of Defense in the past 15 years, as well as successfully licensed various pre-clinical and clinical stage nanotherapeutics to companies such as Celgene/BMS and Fulgent Pharma. Visit https://www.anptinc.com for more information.
Paul's analysis is always worth thinking about!
"May is just a couple of weeks away. I wonder what has the shorts so spooked of late besides those 56M shares shorted with not enough time or sellers to cover. Let’s see now there’s... the earnings report. Probably not though I would love to know how much the Institutional investors have lifted their shares.
*The May 6-8 Vatican conference. Lots of possible worldwide visibility with a top notch PR team would do wonders for Sorrento, and the companies SP.
*The PSS arbitration hearing. Should there be a settlement this year, and not pushed back into next year SP will definitely move upwards.
*Maybe Celularitys scheduled merger this quarter will be in May? It would definitely help turn the screws, but perception wise not enough. Though reality is it’s more easy cash revenue to move trials along should Sorrento choose to do so.
*Announcement of data, and EUA application/approval for Abivertinib (covid). That would sky rocket SP, and definitely a very real possibility for April/May.
*MSC data and EUA very real possibility as well. The MSC P2 Trials are scheduled for multiple sites in US, Brazil, and Mexico, and most likely already ongoing in both Brazil and US.. Most EUA’s are given in P2 trials.
*STIX & ANP are intertwined. STIX EUA means BO ANP, and SP goes straight up.
* AMG trials. The P2 trials are so hush hush you can’t get a peep out of Ji. What would happens if DARPA says we’re taken over, while still in P2, because of outstanding results. SP skyrockets.
* There’s other news that would skyrocket the SP, but probably not until later this year. One last possibility, which could happen anytime this year or next is a minority stake by a big pharma in Sorrento. Even as a minority stake it would be very expensive. It’s fun to dream because several of these events will happen in May, and the rest later this year. The one exception is a big pharma taking a stake in Sorrento. That’s a wild card. Know what you own."
I like this persons thinking !
"If you own 20 shares ($250) or more of SRNE, you will have a substantial sum of money after this all plays out! Think about the 60+ programs SRNE is running simultaneously. If each one adds just .50 to current value, Sorrento is a $30 stock today. But we all know that only 1 success could equal 30 dollars in value. Now imagine just 10% of the projects succeed, and we're staring down 180 bucks a share! Your slim 20 shares position is now worth 3,600 bucks. I've got news for you, though...
10% success rate would be a horrendous outcome based on the late stages of advancement many of these programs are achieving! I'm expecting the success rate will be in the 40% range, conservatively. That equates to 720 bucks a share, and now you are looking at a cool, hard $14,400... Not too shabby!
But hang on!!!
Genius Ji has several external programs and a major lawsuit (or 2) in addition that are each worth into the billions! SRNE @ 1,000 is no pipe dream, but is going to be a genuine reality if only a portion of these exciting scientific/medical breakthroughs come through.
Don't look a gift horse in the mouth. Buy low, hold long, sell very high!"
Celularity Gains FDA Orphan Drug Status on Strength of Placental Stem Cell Trials
Published: Apr 13, 2021 By Gail Dutton
Stem Cells
On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its off-the-shelf natural killer cell therapy for malignant gliomas.
The news coincided with the American Association for Cancer Research (AACR) Annual Meeting 2021, where Celularity delivered an oral presentation and two posters. Each showcased the viability of that therapeutic compound, CYNK-001, as a treatment for multiple, disparate indications.
The presentations focused on CYNK-001 as an off-the-shelf therapeutic for both COVID-19 and for glioblastoma, but this non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy also is being developed for leukemia. It is in Phase I trials for glioblastoma multiform (GBM), and was granted Fast Track designation by the FDA last month.
CYNK-001 is based on an earlier candidate, PNK-007, currently in trials for multiple myeloma and acute myeloid leukemia (AML). The difference between the two, Robert J. Hariri, M.D., Ph.D., founder, chair and CEO of Celularity, explained, is that “CYNK-001 is validated and cryopreserved.” Therefore, it may be an off-the-shelf allogeneic therapy with a long shelf-life.
The COVID-19 trial was the first time CYNK-001 was used for a non-cancer indication. The trial measured safety and efficacy. Results showed the infusions “generally were well-tolerated and three of four patients experienced improvements in oxygenation, inflammatory markers and radiographic findings,” according to the abstract.
In gastric cancer, the overexpression of human epidermal growth factor receptor 2 (HER2) has been reported in about 20% of all cases and is linked to poor outcomes. Another compound, CYNK-101, showed synergistic anti-tumor antibody dependent cellular cytotoxicity when administered with Trastuzumab in vitro, ex vivo and in vivo.
Notably, “It is exactly the same candidate in each of those programs,” Hariri told BioSpace.
That one therapy has such diverse applications is possible because of its origin: placental stem cells.
“The biology of the placenta is remarkable,” Hariri said. “It’s nature’s stem cell factory. We originally thought it was merely a vascular interface between the baby and mother, but it’s actually a life-support system to create an environment for the proliferation and differentiation of stem cells that derive from the primordial stem cell created at fertilization.”
Specifically, “The placenta produces natural killer (NK) cells that are part of the innate immune system,” defending fetuses from infectious diseases and cancer. “One in one thousand women have cancer during pregnancy, yet the incidence of transfer is essentially non-existent,” he pointed out.
That’s because of the NK cells that, likewise, protect the baby from viral infections.
“Placental NK cells recognize stress antigen found on infected cells,” Hariri continued. “Adult-derived NK cells don’t express the same array or recognition markers found on placental cells, therefore, the youth of placental cells is important,” because of their unique characteristics.
“Stemness” is one example, he said. “Stemness is a characteristic of stem cells that is associated with their very versatile differentiality. They can access the entire genome of the stem cell to synthesize all the products the stem cell encodes for.” They also have “better proliferative performance, greater persistence and are immunologically naïve, so they haven’t yet developed the self-expression that lets them be targeted by a recipient’s immune system.
“Therefore, therapies derived from placental stem cells may be safer and more potent than those derived from ‘foreign’ cells.” Because the immune system doesn’t see these cells a ‘foreign,’ patients can be retreated as necessary “until you get the response you want.”
Placental stem cells can solve one of the challenges stem cell therapies face: access to raw material. Each post-partum placenta can produce hundreds to thousands of doses, making this a scalable, economic source of high-quality stem cells.
As Celularity looks to the future, “We are very cognizant of being thoughtful regarding the clinical indications we select. This is a very competitive landscape.”
It plans to produce its products inhouse and aims to be a world leader in the manufacture of cellular medicine.
“The key is consistency and reliability” Hariri said.
Because Celularity spun out from Celgene in 2017, its team has years of experience engineering and manufacturing NK cells and other cell types.
“Our headquarters houses GMP manufacturing capabilities with 15 independent production suites, so we can produce a range of products in parallel under rigorous regulatory guidelines,” he said.
Sorrento has eight (8) potential Covid Emergency Use Authorization candidates...all Blockbusters! Here's a partial overview.
1. Covi-Stix rapid accurate virus test
2. Covi-Track rapid accurate antibody test
3. Covi-push 2020 injection
4. Covi-Drops 2020 nose drops
5. Covi-Vax 2020 lipid DNA injection($34 million DARPA funding)
6. Abivirtinib ARDS prevention
7. Covi-MSC Stem Cell ARDS treatment
8. Covi-Shield antibody cocktail(to deal with variants)
Each of these EUA's could be accompanied by government grants and multi-billion dollar international sales. Additionally there would be multi-billion dollar worldwide marketing partnerships. Dr.Ji says there is "humungous" interest from Mexico, Brazil and Europe.
Timing? Some could come in days. Some in weeks. Others in several months.
In addition to these 8 Covid EUA candidates Sorrento has other potential multi $Billion programs ... here are 2 samples from each of the three portfolio areas...with at least 3 with 2021 revenue potential!
NON-OPIOID PAIN
1. SP-102 phase 3 near 100% enrolled, fast track, lumbar/sciatic pain
2. RTX intractable cancer, knee and arthritic pain
COVID
1. rapid, accurate, low cost tests. TRACK, TRACE, STIX
2. 2020 DROPS, injection and plasmid DNA
CANCER
1. Abivirtinib NSCLC phase 3,lymphomas phase 2, prostate IND, lupus
2. SmartPharm plasmid DNA Plus CAR-T and DAR-T and Mayo Clinic ADNAB drugs.
In summary in 2021 I look forward to the advance and/or approval of all 3 Covid tests; all 3 delivery forms of 2020; all 3 uses of Abivirtinib; all 3 applications of RTX; and all 3 non-opioid pain treatments. In 2021 we will start to see the payoff of the SmartPharm , ACEA and Mayo Clinic technology acquisitions. And 2021 will see half a dozen EUA's, settlement of the PSS lawsuit, maturation of the Celularity and ImmunityBio investments, and several large government grants and the beginning of large scale cash flow.
When a Big Pharma which is running out of patent time on their existing portfolio looks at Sorrento they must love the 24 phase 2 and 3 programs...the enormous productive antibody and small molecule libraries ...the ADNAB, SmartPharm , ADC , CAR-T and DAR-T platforms...the near term revenue streams...the generous investment portfolio ...and think very hard about a buy-out, or at least a partnership leading to a buyout !
After ACEA acquisition Sorrento now has over 60 drug programs!
Phase 3, close to EUA or close to market (12 programs)
1. Abivirtinib NSCLC NDA filed China
2. Abivirtinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar
7. SP-102 sciatica
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application
11. Covi-Trace EUA application
12. Cynviloq (part of PSS lawsuit)
Phase 2 (12 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential
4. Covi-Track EUA pre-validation
5. PD-L1 partnered
6. Herceptin delivery partnered
7. Abivirtinib Lymphoma
8. Abivirtinib Covid 19
9. Abivirtinib prostate cancer ph.2 IND
10. Abivirtinib Lupus ph.2 IND
11. Abivirtinib hairy cell leukemia
12. CD47 partnered
Phase 1, IND filed or pre-IND (36+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T IND
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Covi-Drops ph.1
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 pre-IND partnered
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. 1,000,000+ small molecule library
36. Ten quadrillion antibody library
FUNDING? Sorrento has invested wisely and has 8.2 million shares of ImmunityBio, 20 million shares of Celularity and 35% of ImmuneOncia. These are worth many hundreds of millions and the PSS lawsuit will soon be settled with very large potential gains. And it has many attractive programs to partner for upfront, milestone and royalty payments! Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
1776...while discussing ZTlido...Paul commented,
"ZTlido made $40M+ in a chaotic year with the pandemic while others stumbled, and if I’m correct Ji mentioned going forward they expect around $100M revenue annually.
Add that to shares in ImmuneOncia, Celularity, and ImmunityBio plus everything else Sorrento has on their plate, and they have enough cash on hand for trials for several years. But with the approval of SP102, Abivertinib, and RTX all sometime this year or next, I think Sorrento is doing just fine. Let’s toss in a couple of EUA’s, say Abivertinib (covid), MSC, and STIX in near future while where at it."
1776...I am not an expert on marketing...however Sorrento seems to have a superior product. When I first invested in Sorrento it was because I liked both the pain and cancer programs. Subsequently Covid programs have only added value IMO. I expect significant news in all three program areas in the next few weeks and months! I fully expect Sorrento to become a triple digit stock! Current price levels are due to manipulation. I am fully loaded and look forward to the coming news flow. And Sorrento's investment portfolio is outstanding. I like it now more than I did a year ago!
Yes indeed CH! Things are coming along nicely. Those who criticize simply want more cheap shares.
Mature investors know that markets can be volatile, market sectors can be volatile and individual stocks can be volatile. I chose to invest in the volatile small Biotech sector. My favorite in this sector is Sorrento.
Sorrento provides diversity in one stock! It has potential blockbusters in non-opioid pain, cancer and Covid programs. Here are a few examples....
Sorrento has potential pain blockbusters in RTX and SP-102.
Sorrento has potential cancer blockbusters in Abivirtinib, dozens of ADNAB, DAR-T and ADC drugs!
Sorrento also has potential Covid blockbusters in Abivirtinib, Covi-MSC and 3 delivery formulations of 2020 all with potential EUA's!
And it has great financial strength in its very wise investments and ability to partner dozens of drugs for up-front, milestone and royalty payments!
These are just a few examples of the strengths of Sorrento ... those who've done their dd can think of many more!
"Wonk" found this independant article which highlights Abivirtinib!
"While we are awaiting the abivertinib preliminary results for its phase 2 Covid19 trial, you may find interesting a new study (pre-proof) from European Journal of Pharmacology.
Methodology from the study:
"This paper focuses on identifying inhibitors that target SARS-CoV-2 proteases, PLPRO and 3CLPRO, which control the duplication and manages the life cycle of SARS-CoV-2. We have carried out detailed in silico Virtual high-throughput screening using Food and Drug Administration (FDA) approved drugs from the Zinc database, COVID-19 clinical trial compounds from Pubchem database, Natural compounds from Natural Product Activity and Species Source (NPASS) database and Maybridge database against PLPRO and 3CLPRO proteases."
The authors concluded abivertinib to be a potential top contender to tackle Covid19 based on the screening criteria of the study. Abivertinib was also recommended by the study's authors in their conclusion as a starting point to in the attempt develop Covid19 drug/treatment from existing pharma compounds."
Link to full text:
https://www.sciencedirect.com/science/article/pii/S0014299921002351
HERE ARE MY TOP 10 Sorrento SURPRISES OVER THE PAST 12 MONTHS.
1. ACEA acquisition
2. SmartPharm acquisition
3. ADNAB(MAYO clinic program) acquisition
4. 2020 Covid Mab triple program
5. DARPA $34 Million Covid grant
6. RTX pain program
7. DAR-T program program potential(10-100 times CAR-T potency)
8. COVI-MSC result against ARDS.
9. ABIVIRTINIB potential in cancer and Covid
10. STRONG FUNDING! Sorrento has invested wisely and has 8.2 million shares of ImmunityBio, 20 million shares of Celularity and 35% of ImmuneOncia. These are worth many hundreds of millions and the PSS lawsuit will soon be settled with very large potential gains. And it has many attractive programs to partner for upfront, milestone and royalty payments! Huge portfolio AND huge assets!
Sorry I can't be certain. I do expect several but as I am not certain I do not want to mislead you. I have done a lot of small biotech investing and have learned to be very patient. Sorrento has pleasantly surprised me several times in this past year! April and May could be very good for news...but I am very patient with a stock I expect to hit triple digits.
Critics don't think Sorrento will score on any of these near term shots on goal?
Phase 3 or close to EUA (11 programs)
1. Abivirtinib NSCLC
2. PD-L1 partnered
3. Erbitux biosimilar
4. Xolair biosimilar
5. Remicade biosimilar
6. SP-102 sciatica
7. RTX Osteo Arthritis
8. RTX cancer pain
9. Covi-Stix EUA application
10. Covi-Trace EUA application
11. Cynviloq (part of PSS lawsuit)
If anyone doubted Dr. Ji is building a world-class Big Pharma they should think again! This is headed for multi-triple digits! These are the early days.
Sorrento now has over 50 drug programs AND ACEA portfolio!
Phase 3 or close to EUA (11 programs)
1. Abivirtinib NSCLC
2. PD-L1 partnered
3. Erbitux biosimilar
4. Xolair biosimilar
5. Remicade biosimilar
6. SP-102 sciatica
7. RTX Osteo Arthritis
8. RTX cancer pain
9. Covi-Stix EUA application
10. Covi-Trace EUA application
11. Cynviloq (part of PSS lawsuit)
Phase 2 (11 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential
4. Covi-Track EUA pre-validation
5. PD-L1 partnered
6. Herceptin delivery partnered
7. Abivirtinib Lymphoma
8. Abivirtinib Covid 19
9. Abivirtinib prostate cancer ph.2 IND
10. Abivirtinib Lupus ph.2 IND
11. CD47 partnered
Phase 1, IND filed or pre-IND (28+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T IND
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Covi-Drops ph.1
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1
17. TROP2 pre-IND partnered
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
FUNDING? Sorrento has invested wisely and has 8.2 million shares of ImmunityBio, 20 million shares of Celularity and 35% of ImmuneOncia. These are worth many hundreds of millions and the PSS lawsuit will soon be settled with very large potential gains. And it has many attractive programs to partner for upfront, milestone and royalty payments! Huge portfolio AND huge assets!
AND now Sorrento has ACEA’s major assets which include:
Worldwide Abivertinib (in oral capsule form), a next generation, dual EGFR mutant and BTK inhibitor (BTKi) with a completed NSCLC registrational/Phase 3 trial, Phase 1 B-cell lymphoma study, and ongoing Phase 2 trials in COVID-19 patients with ARDS, and Phase 2 studies for prostate cancer, systemic lupus erythematosus and the ultra-orphan indication of hairy cell leukemia.
AC0058, a brain-penetrating, next generation BTK inhibitor in a Phase 1b Lupus trial and IND-enabling studies for multiple sclerosis.
AC0939, a next generation FLT-3 inhibitor, is near completion of IND-enabling studies for potential CNS indications.
A 1,000,000+ compound library of small molecules and proprietary discovery platform for screening and optimizing potent drug candidates for potential indications in oncology, autoimmune diseases, CNS diseases and infectious diseases.
A biopharma campus of over 23 acres of land with cGMP facilities for producing APIs and capsules for existing and future drug products.
An experienced team of research, development and manufacturing staff for global drug development.
I agree with M that triple digits share prices are coming for certain! And I agree with M that a buyout offer is likely. And I also agree that the first offer could be around $135 a share. But I think there will be a bidding war. There are too many Big Pharmas with rapidly emptying pipelines and Sorrento has more potential blockbusters than any other small biotech on this planet. 3 or 4 bidders would not surprise me. And $135 would only be the opening bid!
Interesting opinions from M.
"Covid is a Global War and SRNE is an Arms Dealer
Once SRNE gets 2-3 EUA’s from FDA, with approval from Brazil / Mexico / Europe, etc. to follow, SRNE will be able to sell every Covi-Stix test, every 5656 pill, and every 8282 dose they and their partners can supply. Based on interim updates that Dr. Ji has publicly shared thus far, that’s the low hanging fruit to push SRNE north of $50/sh by 6/30.
In Q3, what happens with (i) SP-102, (ii) Abivertinib approval for NSCLC in China, and (iii) clinical progress on AMG-2020, Covi-Drops plus Covi-Shield will help Wall Street to clarify the full value of SRNE’s late-stage pipeline and revenue opportunity. The money cards are SP-102 and Abivertinib for NSCLC.
If we miss on (i) and (ii), then Wall Street focus stays 100% Covid. But if we have positive scientific results on SP-102 or an approval in China on NSCLC, SRNE SP will explode towards triple digits !! JP Morgan and Goldman, kings of the fee business and hired guns to Big Pharma, will organize an auction so fast that guarantees Dr. Ji exercises 100% of his options above $135/sh, and the winning Big Pharma bidder walks with SRNE in a merger (cash and stock) in 1Q22 ??
Doesn’t matter if SRNE hits the motherload this summer, no one’s going to allow SRNE to become a $200BL-300BL. Business doesn’t work like that. Pharma industry is more Five Families and less Alice in Wonderland. FDA, Fauci and ALL politicians are in the pocket of Big Pharma, a revolving door of second careers, lucrative consulting and fungible lobbying fees. Ji knows this too, $135/sh strike price on his last tranche of options was not some random number. Ji’s telegraphed his number.
Know what you own. GLTA !"
Sorrento has over 50 drug programs!
Phase 3 or close to EUA (11 programs)
1. Abivirtinib NSCLC
2. PD-L1 partnered
3. Erbitux biosimilar
4. Xolair biosimilar
5. Remicade biosimilar
6. SP-102 sciatica
7. RTX Osteo Arthritis
8. RTX cancer pain
9. Covi-Stix EUA application
10. Covi-Trace EUA application
11. Cynviloq (part of PSS lawsuit)
Phase 2 (11 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential
4. Covi-Track EUA pre-validation
5. PD-L1 partnered
6. Herceptin delivery partnered
7. Abivirtinib Lymphoma
8. Abivirtinib Covid 19
9. Abivirtinib prostate cancer ph.2 IND
10. Abivirtinib Lupus ph.2 IND
11. CD47 partnered
Phase 1, IND filed or pre-IND (28+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T IND
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Covi-Drops ph.1
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1
17. TROP2 pre-IND partnered
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
FUNDING? Sorrento has invested wisely and has 8.2 million shares of ImmunityBio, 20 million shares of Celularity and 35% of ImmuneOncia. These are worth many hundreds of millions and the PSS lawsuit will soon be settled with very large potential gains. And it has many attractive programs to partner for upfront, milestone and royalty payments! Huge portfolio AND huge assets!
SRNE to Sponsor and Speak at Vatican INTL Healthcare Conf. May 6-8 (virtual)
Something BIG is cooking !!! Re post from Henry M on Investor.village
SRNE has been invited to the TOP table - the 5th International Vatican Healthcare Conference the first week of May.
This is a SUPER high profile event and SRNE wants to be noticed. Along with being a PLATINUM sponsor, SRNE speakers include Dr. Ji and SRNE board member, Dr. Robin Smith.
Other conference speakers include: Dr. Fauci, Dr. Collins head of NIH, 2 former FDA commissioners (Gottlieb + von Eschenbach), CEO of Moderna, Ray Dalio from Bridgewater Associates, Deepak Chopra, Dr. Bob Hariri from Celularity, and lots of other very heavy hitters. While the invitees are mostly leaders from the world of medicine globally, we can assume this year’s conf. theme will be COVID.
Anyone else think Dr. Ji will have a good news update re: STI-5656 from USA/Brazil P2 trials ? What about MSC patient updates with more stories of Lazarus like recoveries where more Covid ARDS patients are walking out of the ICU/hospital after getting 3 treatments in 5 days versus going to a morgue.
A lot can happen in 5 weeks. May be even FDA finally grants an EUA for Covi-Stix ! At minimum, SRNE is about to be discovered by a much larger audience!
NICE TO HAVE 49% OF THESE DRUGS (Info from ImmuneOncia website}
IMC-001 (anti-PD-L1 mAb)
PD-L1 is a clinically validated immune-checkpoint target which is over-expressed on tumor cells and tumor-infiltrating immune cells in multiple tumor types. PD-L1 inhibits the natural anti-tumor immune response in the following ways. It prevents recruitments of new T cells to the tumor by preventing priming and activation of new T cells in the lymph nodes. Also, it deactivates cytotoxic T cells in the tumor microenvironment. Antibodies blocking PD-L1 can reactivate T-cell activity and proliferation, which leads to enhanced anti-tumor immunity.
IMC-001 is a fully human anti-PD-L1 IgG1 type monoclonal antibody which has shown promising results in terms of safety and efficacy in the dose-escalation first-in-human study despite the patients were heavily pretreated. IgG1 type antibody targeting PD-L1 on tumor enables unique combinations, such as with a NK cell-based therapy, which is unique in its property among other PD-1/PD-L1 targeting agents. We have received an approval for a multi-regional Phase II study of IMC-001 in Korea, and clinical trial application (CTA) in China is planned in 2Q2020.
IMC-002 (anti-CD47 mAb)
CD47 is a transmembrane protein broadly expressed on cell’s surface and often overexpressed on cancer cells. CD47 on cancer cells interacts with a myeloid inhibitory immunoreceptor SIRPa on macrophages to deliver a “don’t-eat me” signal inhibiting phagocytic activity (cancer cell killing). Blocking CD47-SIRPa interaction restores phagocytic activity of macrophages. Blocking the interaction shows a clear clinical benefit especially when combined with other agents for enhancing the pro-phagocytic signal. However, because CD47 is also expressed on normal cells such as red blood cells (RBCs), first-generation clinical-stage CD47 blockers which shows binding to RBCs were found to cause significant adverse events such as anemia.
IMC-002 is a fully human IgG4 type monoclonal antibody that was engineered to maximize efficacy (tumor phagocytosis) without causing hemagglutination. IMC-002 is highly differentiated as it does not bind to RBCs even at the high concentration of micro-molar range, which is much higher than the clinically effective level. Lack of RBC binding may improve the safety profile and the PK profile by bypassing the ‘antigen sink’ effect. FDA had recently cleared IND application and Phase I study of IMC-002 is being initiated in the U.S. for solid tumors and lymphomas.
Combinational blockade of PD-L1 and CD47 has been shown to enhance anti-tumor effects in vivo. It represents an interesting opportunity to combine IMC-001 and IMC-002 in the clinic. ImmuneOncia is also currently developing additional antibodies targeting novel immune-checkpoints.
ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China
Tue, March 30, 2021, 6:00 PM·4 min read
3D Medicines to Lead the Manufacture, Clinical Development and Commercialization of IMC-002 for Oncology indications in Greater China
ImmuneOncia to Receive potentially up to $470.5M including $8M Upfront, and Future Development and Commercial Milestone Payments, plus Tiered Royalties on Net Sales
SEOUL, South Korea, March 30, 2021 /PRNewswire/ -- ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology company in South Korea, and 3D Medicines, Inc., a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, today announced an exclusive license agreement for the development, manufacture and commercialization of IMC-002, ImmuneOncia's monoclonal antibody against CD47. The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China (Mainland China, Hong Kong, Macau, and Taiwan). ImmuneOncia will retain rights of IMC-002 in the rest of the world including the United States, European Union, and Japan.
Under the terms of the agreement, ImmuneOncia will receive an upfront payment of $8 million from 3D Medicines. Additionally, ImmuneOncia is eligible to receive up to $462.5 million upon the achievements of all future development and commercial milestones, plus tiered royalties up to double-digits on annual net sales of IMC-002 in Greater China. In exchange, 3D Medicines will receive rights to develop, manufacture and commercialize IMC-002 in Greater China. 3D Medicines is planning to file IND to NMPA in China this year.
"3D Medicines is an established leader in oncology, with a track record of successfully developing in-licensed oncology programs." said Yun Jeong Song, Chief Executive Officer of ImmuneOncia. "We are confident that 3D Medicines is the ideal partner as we enter into our collaboration and look forward to accelerating our delivery of IMC-002 to patients in Greater China."
"We are very pleased to enter into this exclusive collaboration with ImmuneOncia" said John Gong, M.D., Ph.D., Chairman and Chief Executive Officer of 3D Medicines. "We believe that IMC-002, used in combination with existing standard of care therapeutics or Envafolimab, an innovative subcutaneous PD-L1 antibody which we have just filed for marketing approval in China, could alter the treatment paradigm across various tumor types."
YAFO Capital (Shanghai) Co. Ltd. acted as financial advisor on this transaction for ImmuneOncia.
About IMC-002
IMC-002 is a fully human IgG4 monoclonal antibody designed to block the CD47–SIRPa interaction in order to promote the phagocytosis of cancer cells by macrophages. According to its non-clinical results, it binds to human CD47 with an optimal affinity that maximizes efficacy without binding to RBCs or causing anemia which is often seen in other CD47 blocking agents under development. For more information about the Phase 1 clinical trial, visit clinicaltrials.gov, identifier number NCT04306224.
About ImmuneOncia Therapeutics, Inc.
ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan Corporation in South Korea and Sorrento Therapeutics, Inc. in U.S. ImmuneOncia leverages both companies' expertise in drug development and antibody engineering. The company's mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide, and its portfolio includes diverse immune checkpoint antibodies. ImmuneOncia has successfully completed a Phase I study of IMC-001, its leading candidate anti-PDL1 antibody, and a Phase II study was initiated in 2H 2020.
For more information, please visit www.immuneoncia.com.
The prevalence and years lived with disability caused by low back pain in China, 1990 to 2016: findings from the global burden of disease study 2016
Aimin Wu 1, Wenlan Dong 2, Shiwei Liu 2, Jason Pui Yin Cheung 3, Kenny Yat Hong Kwan 3, Xinying Zeng 2, Kai Zhang 1, Zhenyu Sun 1, Xiangyang Wang 4, Kenneth Man Chee Cheung 3, Maigeng Zhou 2, Jie Zhao 1
Affiliations expand
PMID: 30234697 PMCID: PMC6319591 DOI: 10.1097/j.pain.0000000000001396
Free PMC article
Abstract
The aim of this work was to quantify the prevalence and years lived with disability (YLDs) caused by low back pain (LBP) in China from 1990 to 2016. Data from the GBD 2016 (Global Burden of Diseases, Injuries, and Risk Factors Study 2016) were used. We analyzed the age-sex-province-specific prevalence and YLDs for LBP of 33 provinces/regions in China. Comparisons were made with the data retrieved from the 1990 GBD study. We estimated that 5.45 × 10 individuals had LBP in 1990, which rose to 6.73 × 10 in 2016. The age-standardized prevalence of LBP decreased from 5.6% (95% uncertainty interval [95% UI]: 4.9%-6.3%) in 1990 to 4.2% (95% UI: 3.8%-4.8%) in 2016. The YLDs for LBP increased from 6.2 million (95% UI: 4.3-8.3 million) in 1990 to 7.7 million (95% UI: 5.4-10.2) in 2016. Age-standardized YLD rate (per 100,000 person) decreased from 637.5 (95% UI: 449.9-848.8) in 1990 to 481.9 (95% UI: 338.6-637.0) in 2016. A female preponderance was observed for prevalence and YLDs. The prevalence and YLDs rate for LBP slightly decreased from 1990 to 2016 in China; however, the total individuals and YLDs increased. Low back pain still ranks as the second leading cause of YLD burden disease in China. Considerable attention should be paid for LBP, especially in the female population.
Sorrento is an Emerging BioPharma (EBP).By the end of this year Sorrento could have some 30 drugs in the clinic. Several in phase 3 and about a dozen in phase 2. In 2018 of the 59 new drugs approved seven approvals were based on phase 1 or phase 2 trials.
• Of the 59 new drug launches in 2018, 38 were patented by emerging biopharma companies, and 74% of those were also registered by these companies.
• Although the importance of large pharma in originating molecules is decreasing, they remain important partners for EBP companies even as EBP are increasingly able to commercialize alone.
• Large pharma companies registered nearly half of the new drugs in 2018, approximately half of which originated with emerging biopharma companies.
Anytime Sorrento chooses they can partner new drugs for upfront, milestone and royalty payments. OR they keep the worldwide rights and simply become a Big Pharma!
https://www.healthindustryhub.com.au/wp-content/uploads/2019/05/the-changing-landscape-of-research-and-development.pdf
I find it interesting that PSC said "...we out-licensed our allogeneic stem cell program, including the COVID-19 therapy, to Sorrento Therapeutics." Apparently Sorrento has licensed the ENTIRE allogenic stem cell program, of which the Covid 19 program is only a part! What are the OTHER APPLICATIONS ? This technology could have many applications. I would to hear more about this! It looks like another potential blockbuster deal by Dr. Ji!
More from PSC website:
First Patients Treated in COVID-19 Stem Cell Clinical Trial
Feb 19, 2021
In 2020, Personalized Stem Cells developed and secured FDA approval for a COVID-19 stem cell clinical trial. In October of last year, we announced that we out-licensed our allogeneic stem cell program, including the COVID-19 therapy, to Sorrento Therapeutics. Recently, Sorrento announced that the first clinical trial participants received stem cell therapy for COVID-19.
Stem Cell Therapy for COVID-19
Infection with COVID-19 can lead to Acute Respiratory Distress Syndrome (ARDS). ARDS is a serious lung condition that is typically characterized by an acute inflammatory response which leads to fluid buildup in the lungs and ultimately low blood oxygen levels. ARDS may lead to long term complications or death.
When administered intravenously, mesenchymal stem cells (MSCs) travel to the lungs. MSCs have demonstrated the ability to down regulate inflammation and inhibit lung fibrosis (scar tissue). Additionally, MSCs have been shown to aid in clearing fluid from the lungs and may lead to lung tissue regeneration. These, among other mechanisms of action, make stem cell therapy a potentially viable treatment option for the serious lung complications that can result from infection with COVID-19.
For more information about stem cell therapy for COVID-19, read a literature review published by PSC doctors and collaborating scientists discussing "the rationale behind using stem cells to treat patients with COVID-19".
COVID-19 Stem Cell Clinical Trial
Patients participating in the COVID-19 clinical trial will receive one injection of stem cells every other day for a total of three injections. The stem cell treatments, termed COVI-MSC™ by Sorrento, are administered intravenously. According to Sorrento’s recent announcement, four patients have completed the stem cell treatments and all four have been discharged from the hospital.*
According to Sorento, there have been no infusion related adverse events reported in any of the patients. As a phase 1b study, the primary objective of the clinical trial is to focus on the safety of the stem cell treatments. While the preliminary safety data looks promising, the preliminary efficacy data looks equally as promising.1
* now 9 of 9 released from ICU and hospital a few days after treatment.
1 "At the request of the White House Coronavirus Task Force, PSC submitted an Investigational New Drug (IND) application to the FDA in April 2020 and received approval in July 2020. PSC, which primarily focuses on orthopedics, went on to grant global rights to its adipose-derived allogeneic mesenchymal stem cell (MSC) program, including the COVID-19 therapy candidate, to Sorrento Therapeutics in October 2020.
As discussed in a peer-reviewed scientific article published by PSC and collaborating scientists on the rationale behind using stem cells to treat COVID-19, MSCs have demonstrated the capacity to inhibit lung damage, reduce inflammation, dampen immune responses and aid with alveolar fluid clearance. Additionally, MSCs produce molecules that are antimicrobial and reduce pain. Recently, the application of MSCs in the context of ongoing COVID-19 disease and other viral respiratory illnesses has demonstrated reduced patient mortality and, in some cases, improved long-term pulmonary function."
From PSC website:
Stem Cell Sources: Adipose vs. Bone Marrow
Mar 19, 2021
While there are several sources of mesenchymal stem cells (MSCs), two of the most common sources include adipose tissue and bone marrow. At Personalized Stem Cells, we process adipose (fat) tissue to extract and concentrate MSCs for use in FDA-approved clinical trials.
Why Adipose Tissue?
Our founders developed PSC after 15 years of experience with adipose-derived stem cell therapy in animals. Over 14,000 veterinary patients have received their own fat-derived stem cells to treat conditions such as osteoarthritis, injured tendons, and ligaments, as well as internal medicine conditions such as chronic kidney disease. Many animal patients have experienced a better quality of life as a result of treatment with stem cell therapy.
Adipose tissue has been shown to contain as much as 500 times the amount of stem cells as bone marrow. Thus, stem cells can be collected in far greater numbers from fat than they can from a sample of bone marrow aspirate. In addition, adipose tissue can be easily collected and is generally a readily available source. Let’s be honest, most of us can spare a little extra fat!
What is Bone Marrow Aspirate Concentrate?
While we solely process adipose-derived stem cells (ADSCs), some doctors use Bone Marrow Aspirate Concentrate (BMAC). BMAC is a sample of bone marrow that is aspirated from a patient’s bone and then concentrated for injection. Like adipose, bone marrow contains therapeutic cells including MSCs, growth factors, and proteins that contribute to healing. Typical BMAC procedures are performed in a doctor’s office and can be completed in a few hours.
Like ADSCs, BMAC is used to treat orthopedic conditions such as osteoarthritis and soft tissue injuries. As we mentioned above, however, bone marrow contains far fewer stem cells than adipose. On top of that, many providers who use BMAC in a clinical setting do not have the ability to perform essential testing on the sample such as cell counts, viability, and sterility.
Testing to Ensure Viability and Sterility
Testing of stem cell samples is an important part of the process. Knowing exactly how many cells are in each dose as well as the viability of those stem cells is essential to providing a therapeutic amount of healthy, living stem cells. Sterility testing is also crucial to a successful stem cell treatment. By performing sterility tests and endotoxin testing, we assure that stem cell doses are free of potentially harmful contaminants.
With in-clinic BMAC procedures, there is no way to count cells or to determine cell viability (health of the cells). In addition, without the ability to perform sterility testing, there can be no guarantee that the sample is not contaminated, which may lead to a higher rate of adverse reactions, such as an infection at the treatment site.
Do Research to Determine the Best Option for You
As with any medical procedure, it is important to do your research before undergoing treatment. While both adipose and bone marrow contain therapeutic stem and regenerative cells that can be used for healing, we believe adipose to be a superior source of cells. In addition, having your cells processed at an outside laboratory, in an aseptic, FDA inspected facility, adds a level of safety that may not be possible in a clinical setting. Also, and perhaps most important, stem cells are considered a drug and therefore must be used only as part of an FDA-approved Investigational New Drug program. The FDA warns against stem cell procedures that are not FDA approved or part of an FDA-approved clinical trial.
Not all MSC's are equal. Mesoblast's phase 2 trial failed! I understand they were Bone Marrow derived.
PSC claims adipose stem cells are more easily procured, less likely to be damaged, and are very durable.
Why use adipose sourced stem cells?
"MSCs are abundant in adipose tissue and highly potent. Human ASCs have significant advantages over MSCs derived from other sources because they are obtained from a minimally invasive lipoaspiration procedure [33]. The MSC concentration in adipose is greater than all other tissues in the body [34, 35] and the potency is maintained with age of the donor [36], unlike bone marrow derived MSCs [37, 38]. Significant numbers of ASCs can be obtained due to accessibility to the subcutaneous adipose tissue and the volume that can easily be extracted. Taken together, the ASC has advantages in both autologous use and allogeneic use. Significant antiinflammatory effects have been confirmed in many veterinary and human clinical studies [39–41]."
This is from the following study.
Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients
Christopher J. Rogers1*, Robert J. Harman1, Bruce A. Bunnell2, Martin A. Schreiber3, Charlie Xiang4, Fu-Sheng Wang5, Antonio F. Santidrian6 and Boris R. Minev6,7
Abstract
In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organiza-tion declared that the rapidly spreading viral outbreak had become a global pandemic. Coronavirus disease 2019 (COVID-19) is typically associated with fever and respiratory symptoms. It often progresses to severe respiratory distress and multi-organ failure which carry a high mortality rate. Older patients or those with medical comorbidi-ties are at greater risk for severe disease. Inflammation, pulmonary edema and an over-reactive immune response can lead to hypoxia, respiratory distress and lung damage. Mesenchymal stromal/stem cells (MSCs) possess potent and broad-ranging immunomodulatory activities. Multiple in vivo studies in animal models and ex vivo human lung models have demonstrated the MSC’s impressive capacity to inhibit lung damage, reduce inflammation, dampen immune responses and aid with alveolar fluid clearance. Additionally, MSCs produce molecules that are antimicrobial and reduce pain. Upon administration by the intravenous route, the cells travel directly to the lungs where the majority are sequestered, a great benefit for the treatment of pulmonary disease. The in vivo safety of local and intravenous administration of MSCs has been demonstrated in multiple human clinical trials, including studies of acute respiratory distress syndrome (ARDS). Recently, the application of MSCs in the context of ongoing COVID-19 disease and other viral respiratory illnesses has demonstrated reduced patient mortality and, in some cases, improved long-term pulmonary function. Adipose-derived stem cells (ASC), an abundant type of MSC, are proposed as a therapeutic option for the treatment of COVID-19 in order to reduce morbidity and mortality. Additionally, when proven to be safe and effective, ASC treatments may reduce the demand on critical hospital resources. The ongoing COVID-19 outbreak has resulted in significant healthcare and socioeconomic burdens across the globe. There is a desperate need for safe and effective treatments. Cellular based therapies hold great promise for the treatment of COVID-19. This literature summary reviews the scientific rationale and need for clinical studies of adipose-derived stem cells and other types of mesenchymal stem cells in the treatment of patients who suffer with COVID-19.Keywords:COVID-19, SARS-CoV-2, ARDS, Pneumonia, Mesenchymal stem cells
Weeks ago they reported on 4 patients. Now they reported on 9 patients It IS NEWS whiney!
The exciting thing is that this technology should work equally well against any Covid variant . Good to see trials in Brazil, Mexico as well as US! This will help empty overcrowded ICU's...Many countries hospitals are easily overwhelmed .
9 for 9 lives saved! Out of the ICU and hospital in a few days! And planning for an EUA worthy phase 2! "Currently, Sorrento is working with the FDA to plan a placebo-controlled Phase 2 study to be conducted across multiple sites in the United States, Brazil and Mexico, and to determine the sample size and data necessary to support an emergency use authorization (EUA)." Win-win-win! Sorrento's in the life saving business.
I was asked if I had confidence in Sorrento's Covid portfolio. We should soon hear about the rapid accurate tests. Meanwhile I expect near-term news about both Abivertinib and Covi-MSC progress. I have great confidence in the 3 forms of 2020. And I look forward to news about the pan-variant antibody cocktail.
I was very pleased to hear that Sorrento now owns 100% of Scilex. It will be a real cash cow with SP-102 and RTX approvals and ARD-301 for long haulers could be big.
And Abivertinib , ADNAB, plasmid DNA and Dar-T in dozens of cancer applications have oustanding potential. These are all first-in-class and best-in-class IMO.
But I must admit I am amazed by the Celularity and ImmunityBio investment potential. And if there's any justice in this world PSS will soon be handing over $1+ billions to Sorrento. I've never before invested in such a well funded...wide portfolio...small biotech!